Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition

div > div.group > p:first-child"> In January, Bristol-Myers Squibb announced its plans to buy cancer drugmaker Celgene in a cash and stock deal valued at $74 billion.

Wellington Management is the largest institutional holder of Bristol's common stock at about 8 percent. Wellington said in a release that it"does not believe that the Celgene transaction is an attractive path towards" business that"secures differentiated science and broadens the future revenue base."

Wellington said the acquisition asks Bristol's shareholders to accept too much risk while there are other paths to create value for shareholders. The investment company also worries the execution of the acquisition will be more difficult than depicted by company management.Celgene has also been working on an experiential gene therapy that is a highly competitive and potentiality profitable area of the biotech industry.

Synergies almost never end up creating the shareholder value expected. See KHC over last 2 years.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Warren Buffett says he was close to making a 'very large' acquisition in the fourth quarterBuffett says he was close to making a 'very large' acquisition in the 4th quarter but it fell apart Moscow is looking for a big tower. he could give some to me, ill put it to good use. askwarren Would you buy a Company that's involved with Media and or advertising?
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »

Warren Buffett says prospects poor for 'elephant-sized acquisition'Warren Buffett is hunting for 'an elephant-sized acquisition,' but he ... Sheesh Yup so all those billions in tax cuts wont grow the economy. He’s going to buy back stock. LEAVE. THE. ELEPHANTS. ALONE. OLD. MAN.
출처: Reuters - 🏆 2. / 97 더 많은 것을 읽으십시오 »